Status:
UNKNOWN
Daptomycin Pharmacokinetics in Continuous Veno-venous Hemodiafiltration
Lead Sponsor:
University of Zurich
Conditions:
Bacteremia
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
The purpose is to investigate daptomycin pharmacokinetics in critically ill patients with suspected or verified bacteremia with Gram-positive cocci undergoing combined continuous hemodiafiltration at ...
Eligibility Criteria
Inclusion
- male or female of 18 years or older
- females: negative pregnancy test
- Hospitalisation in the medical ICU
- High suspicion or evidence of Gram-positive infections requiring antibiotic therapy
- Subjects receiving standard antibiotic treatment for Gram-positive infection
- Evidence of renal failure
- Clinical necessity for continuous renal replacement therapy
- Written informed consent signed by the patient or a next of kin and an independent physician in case the patient is not able to sign.
Exclusion
- Skeletal muscle disorders or CPK levels of \> 2 x ULN
- History of hypersensitivity to the drug
- Participation in another study
- Subjects with a history of muscle disease
- Patients with severe liver function impairment (Child C)
- Life expectancy of less than 5 days
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01171547
Start Date
February 1 2010
Last Update
July 28 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Intensive Care Unit, University Hospital Zurich
Zurich, Canton of Zurich, Switzerland, 8091